MIM
ATXS

Monashee Investment Management’s Astria Therapeutics ATXS Stock Holding History

Monashee Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,833
Closed -$330K – 87
2019
Q3 		$330K Buy
+10,833
New +$428K 0.15% 85
2015
Q2 		– Hold
0
– – – 53

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Monashee Investment Management's ATXS Position: Q4 2019 in Review

Monashee Investment Management sold out of Astria Therapeutics (ATXS) in Q4 2019, closing a stake of 10,833 shares — an estimated $330K sold.

Monashee Investment Management first reported a position in ATXS in Q3 2019 and held it in 1 quarter. The position peaked at $330K in Q3 2019. 28 funds tracked by Wall St. Rank hold ATXS as of Q4 2019.

  • Monashee Investment Management reported no remaining Astria Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Monashee Investment Management sold 10,833 Astria Therapeutics shares in Q4 2019, an estimated $330K.
  • Monashee Investment Management first reported a position in Astria Therapeutics in Q3 2019 and held it in 1 quarter.
  • Monashee Investment Management's Astria Therapeutics position peaked at $330K in Q3 2019.
  • 28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2019.

Based on Monashee Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.